Cracking The Code: Understanding Analyst Reviews For AtriCure
In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $58.00 and a low estimate of $32.00. A 10.66% drop is evident in the current average compared to the previous average price target of $49.25.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive AtriCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Lowers | Buy | $40.00 | $46.00 |
| Suraj Kalia | Oppenheimer | Announces | Outperform | $32.00 | - |
| Mike Matson | Needham | Maintains | Buy | $46.00 | - |
| Danielle Antalffy | UBS | Raises | Buy | $58.00 | $57.00 |
| Rick Wise | Stifel | Lowers | Buy | $42.00 | $50.00 |
| Mike Matson | Needham | Raises | Buy | $46.00 | $44.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AtriCure's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on AtriCure analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into AtriCure's Background
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
AtriCure's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, AtriCure showcased positive performance, achieving a revenue growth rate of 21.03% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -9.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AtriCure's ROE stands out, surpassing industry averages. With an impressive ROE of -2.11%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): AtriCure's ROA stands out, surpassing industry averages. With an impressive ROA of -1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.16.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.